Logical Therapeutics Appoints Peter A. Lankau as CEO an...(is being developed to provide therapeuti...),Health

In pre-clinical studies, LT-NS001 has demonstrated significantly less damage to the gastrointestinal tract than equimolar doses of naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and multiple-dose clinical studies. In all cases, there were no serious adverse events and LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

The use of NSAIDs is associated with serious side effects, the most frequent being an increased rate of gastric and duodenal ulcers. In the United States alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion a year. Serious NSAID-induced gastrointestinal (GI) complications, such as hemorrhage and perforation, are directly responsible for approximately 20,000 deaths per year in the United States.

Logical Therapeutics is developing LT-NS001 under an exclusive license from Medinox, Inc.

About Logical Therapeutics Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include S V Life Sciences, Burrill and Company, Novo Ventures A/S, and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltherapeutics.com.

Inquiries regarding LT-NS001 should be addressed to our business development department at